1. ALLA AKTIER
  2. NYHETER
  3. AMNIOTICS

Amniotics

Nyheter Amniotics Nyheter alla bolag
Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar!

Amniotics enters into a liquidity providing agreement with Lago Kapital

MARKN.

Amniotics AB (publ) (“Amniotics” or “the Company”) has entered into a liquidity providing agreement with Lago Kapital AB. In connection with the liquidity providing agreement, Theope Seed Capital AB has received an exemption for its lockup and lent 25,000 shares to Lago. The liquidity providing agreement with Lago Kapital AB will be effective starting on 20.5.2022. Lago Kapital AB will provide liquidity according to Nasdaq Stockholm rules set-out for liquidity providing. The intention is to promote liquidity in the share, and means that the liquidity guarantor quotas the buy and sell volume corresponding to SEK 20,000 with a spread of a maximum of 4% between the buy and sell price.
 
The agreement will be in force initially for a fixed term of three (3) months and thereafter until further notice with a notice period of one (1) calendar month.

For more information please contact

Kåre Engkilde
CEO, Amniotics AB
Phone: +46 (0) 723 27 85 20
Email: ke@amniotics.com
or
Johny Humaloja
CFO, Amniotics AB
Phone: +46 (0) 735 0668 56
Email: jh@amniotics.com

About Amniotics

Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics has also an, by Läkemedelsverket (Swedish MPA), approved Good Manufacturing Practice (GMP) facility to produce Advanced Therapy Medicinal Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now moving into clinical trials with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs.

Amniotics (publ) has it´s headquarter in Lund, Sweden.

Amniotics Certified Adviser on First North is Redeye AB, certifiedadviser@redeye.se, telephone: +46 (0) 8 121 576 90.

The company is listed at Nasdaq First North Growth Market in Stockholm.

Learn more at www.amniotics.com. 

This press release is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.

Attachments

Amniotics enters into a liquidity providing agreement with Lago Kapital

Datum 2022-05-19, kl 18:35
Källa MFN
Bifogade filer
Amniotics enters into a liquidity providing agreement with Lago Kapital